Knowing When to Stop Fertility Treatment

Is there a single right time to stop?

No single milestone tells everyone it is time to stop — not a cycle count, not an age, not a dollar figure. Stopping is a personal decision shaped by four things at once: your realistic prognosis if you continue, what your body and mind can carry, what you can afford, and what building a family means to you. A good clinic helps you see those clearly. It does not decide for you, and it should never pressure you toward one more cycle you have already decided against.

There is no universal stopping point; the honest one is where the odds, the cost, and your own limits stop aligning.

The reason this page is hard to find is that it runs against the momentum of treatment. Each step forward has a next step, and the next step usually has some chance of working. That is true almost indefinitely, which is exactly why 'keep going because it might work' is not, on its own, a decision. A real decision weighs how much it might work against everything it costs to find out.

What the cumulative success curve shows

Fertility treatment works by accumulation, not by a single roll of the dice. One IVF cycle succeeds a minority of the time, but the chances add up across attempts. In a large UK study of more than 156,000 women, the live-birth rate was about 29.5% after the first cycle and rose to roughly 65% by the sixth cycle across all ages 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.First-cycle IVF live-birth rate ~29.5% rising to ~65% cumulatively by the sixth cycle overall, and ~12% rising to ~31.5% by six cycles for women aged 40-42 — the basis for cumulative, age-dependent prognosis in a stop-or-continue decision.. Seeing the whole curve — not just one cycle's odds — is the single most useful thing when weighing whether another try is worth it.

This accumulating figure is the cumulative live-birth rate: the chance of eventually having a baby across several cycles, rather than in any one of them. It is a more honest number than a single cycle's success rate, and it is the number to ask your clinic for by name. But it climbs in a particular shape — early cycles add the most and later cycles add less. The curve does not keep rising at the same pace, and understanding the diminishing returns after multiple IVF cycles is central to knowing when the next attempt is buying very little.

How many cycles that shape justifies is a genuinely individual question, and it depends heavily on the number of ivf cycles already behind you and how you responded to them. A clinic can plot your own version of this curve from how your earlier cycles went.

How age bends the curve

Age is the strongest single force acting on that curve, and it is why two people with identical diagnoses can get very different advice. In the same UK cohort, women aged 40 to 42 had roughly a 12% live-birth rate in the first cycle and about 31.5% by the sixth — less than half the figure for the whole group 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.First-cycle IVF live-birth rate ~29.5% rising to ~65% cumulatively by the sixth cycle overall, and ~12% rising to ~31.5% by six cycles for women aged 40-42 — the basis for cumulative, age-dependent prognosis in a stop-or-continue decision.. National US outcomes reported by the Society for Assisted Reproductive Technology show the same steep decline in live births per egg retrieval across age bands, sharpest after the late 30s 2Ref 2Society for Assisted Reproductive Technology (SART) (2024).National Summary Report (SART CORS Online).US national live-birth rates per egg retrieval decline steeply across age bands, sharpest after the late 30s..

For women aged 40-42 in that cohort, the first-cycle live-birth rate was about 12%, rising to roughly 31.5% by six cycles 1Ref 1Smith ADAC, Tilling K, Nelson SM, Lawlor DA (2015).Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles.First-cycle IVF live-birth rate ~29.5% rising to ~65% cumulatively by the sixth cycle overall, and ~12% rising to ~31.5% by six cycles for women aged 40-42 — the basis for cumulative, age-dependent prognosis in a stop-or-continue decision..

What is declining is mostly egg quality and number, and that is a moving target: each passing year lowers the odds a fresh cycle can deliver. This is the arithmetic behind why some people, at a certain age, are counseled that continuing with their own eggs offers diminishing returns while moving to donor eggs would reset the odds toward those of the younger donor. That is not a verdict about anyone in particular; own-egg versus donor-egg cumulative outcomes differ enough that it belongs on the table as a real option, not a last resort whispered about.

Getting a prognosis for your own situation

National averages describe a population, not you, and the gap between the two is where much of the anxiety lives. The CDC's IVF Success Estimator turns national data into an individualized estimate of your chance of a live birth, using your age, height and weight, and diagnosis, for ages 20 to 50 3Ref 3Centers for Disease Control and Prevention (2024).IVF Success Estimator.The CDC IVF Success Estimator gives an individualized live-birth estimate from age, height/weight, and diagnosis for ages 20-50, based on national averages rather than any single clinic.. It is a reasonable starting point for a conversation, not a verdict, and it is built from national averages rather than any single clinic's results.

One caveat matters when reading any of these numbers. Federal ART figures are reported noncumulatively: each cycle is counted on its own, so a single-cycle success rate understates what two or three cycles together might achieve 4Ref 4Centers for Disease Control and Prevention (2024).NASS Technical Notes.Federal ART figures are reported noncumulatively — each cycle counted separately — so a single-cycle rate understates multi-cycle chances, and per-cycle, per-transfer, and cumulative figures differ.. When a clinic quotes a figure, the first question is which figure it is, because the three common ones describe very different things.

A prognosis you can actually decide on is one built around your own history: your age, your ovarian response, your diagnosis, and how any previous cycles have gone. That is the number worth pressing your clinic for.

Have you tried what actually works?

Before treating a plateau as the end of the road, it is worth confirming that the evidence-based steps have genuinely been tried. For unexplained infertility, ASRM describes a stepwise sequence — a period of expectant management, then ovarian stimulation with insemination, then IVF — each carrying a known trade-off between live-birth rate and the risk of a multiple pregnancy 5Ref 5Practice Committee of ASRM (2020).Evidence-based treatments for couples with unexplained infertility: a guideline.For unexplained infertility, ASRM describes a stepwise sequence (expectant management, ovarian stimulation with IUI, then IVF), each trading live-birth rate against multiple-pregnancy risk.. Knowing where you sit in that sequence, including how many IUIs came before IVF, tells you whether there is a proven next step or only unproven ones left.

The distinction matters because a plateau often gets blamed on not having added enough. In practice, the thing that will not rescue a poor prognosis is an unproven add-on. A randomized trial found that PGT-A — genetic testing of embryos, marketed heavily as a way to raise success — did not improve ongoing-pregnancy rates for good-prognosis patients compared with standard embryo selection 6Ref 6Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.The STAR randomized trial found PGT-A did not improve ongoing-pregnancy rates for good-prognosis patients versus standard morphology-based selection — unproven add-ons do not rescue a poor prognosis.. So the honest question of whether pgt-a actually improves ivf success has a clear answer for most people, and 'we just haven't tried the extras' is rarely the real reason a cycle failed. If the proven steps are exhausted and the odds are genuinely low, that is information, not failure — and it is different from stopping because a clinic has run out of things to upsell.

The costs that don't show up on the invoice

The price of a cycle is the easiest cost to see and the least complete. Treatment also asks for time measured in early-morning monitoring visits, injections, and the emotional whiplash of a two-week wait repeated cycle after cycle. Many people describe the toll as cumulative in its own right — each disappointment landing on the last — and that toll is a legitimate input to the decision, not a weakness to push through. Naming it out loud, to a partner and to a clinician, is part of making a clear-eyed choice rather than being carried along by momentum.

There is no formula that converts heartbreak, savings, and physical strain into a single answer. But there is a fair question to ask at each juncture: is the realistic chance the next cycle offers worth what it will take from you to find out? When the honest answer becomes no — for reasons of prognosis, or money, or simply having reached your limit — that is a sufficient reason on its own. A decision made for your own well-being does not require anyone else's endorsement.

The paths that open when treatment ends

Stopping active treatment is rarely a single door closing; it is usually several others coming into view. For some, the next step is a different biological path — donor eggs or donor sperm, donor embryos, or gestational surrogacy — each of which changes the odds by changing whose gametes or uterus are involved. For others it is adoption or fostering. And for others still, it is building a full life without children, a path that has its own name and a growing body of research behind it; people who reach it, especially with support, often describe a real and lasting adjustment over time rather than permanent grief.

Choosing to stop treatment and choosing what comes next are two decisions, not one, and they do not have to be made in the same week. Living child-free is not the failure of the other options; for many it is the off-ramp they actively choose once they have the full picture. What matters is that the choice is made with real information and, where possible, with support — a counselor, a partner, a peer community — rather than in isolation at the lowest moment.

Making the decision with your clinician

The most useful frame is to treat stopping as a planned decision rather than a collapse. Many clinics will help set this up in advance: agree on a number of cycles to attempt, define what result would count as reason to continue and what would count as reason to stop, and put a review point on the calendar before you are exhausted. Deciding the rule while you are clear-headed protects you from having to decide it in the rawest possible moment.

Stopping is a considered medical and personal choice, not a verdict on your worth or your effort.

Good questions to bring to that conversation are concrete: What is my realistic cumulative chance over the next one, two, and three cycles? What specifically would change if we adjusted the plan? Are there proven options we have not used, or only unproven ones? What would you advise someone you love in my exact situation? A clinician who answers those honestly — including when the honest answer is that the odds are low — is doing the job well. The decision remains yours, and there is no version of it, continue or stop, that you have to justify to anyone else.